Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD) - Report - MDSpire
Advertisement
Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)
Clinical Report: Trends and Key Areas of Research in Type 3 Macular Neovascularization
Overview
This bibliometric analysis identifies key research trends in type 3 macular neovascularization (MNV3) associated with age-related macular degeneration (AMD). It highlights the increasing incidence of MNV3, the leading authors and journals in the field, and emerging research hotspots such as artificial intelligence and biomarkers.
Background
Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries, with wet AMD accounting for the majority of severe vision loss. Type 3 macular neovascularization (MNV3) is a specific subtype of wet AMD that has been increasingly recognized for its distinct pathophysiology and clinical implications. Understanding the evolving landscape of MNV3 research is crucial for improving diagnosis and treatment strategies.
Data Highlights
Year
Publications
Countries
2001-2026
564
97
Key Findings
The United States is the leading country in MNV3 research.
Kim JW is the most prolific author, while Yannuzzi LA is the most cited.
Investigative Ophthalmology & Visual Science published the most papers on MNV3.
High-frequency keywords include 'ranibizumab', 'photodynamic therapy', and 'optical coherence tomography'.
Emerging research hotspots involve 'artificial intelligence', 'biomarker', and 'microglia'.
Research topics are categorized into pathogenesis, imaging, therapy, and clinical prognosis.
Clinical Implications
The findings underscore the importance of ongoing research in MNV3 to enhance diagnostic accuracy and therapeutic options. Clinicians should stay informed about emerging trends and consider the implications of recent studies on patient management and treatment strategies.
Conclusion
This analysis provides a comprehensive overview of the current state of MNV3 research, highlighting significant trends and future directions that may influence clinical practice in managing age-related macular degeneration.
Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.
